Longevity Twitter loves two words: metformin and rapamycin. Both are real drugs with real histories—diabetes care for one, transplant immunosuppression and cancer contexts for the other. Both appear in aging research because metabolic and growth pathways sit near the biology of lifespan in animals.
Human evidence for using them purely to “live longer” in healthy people is not the same as evidence for treating disease. Side effects, interactions, and who should never touch them are not footnotes. They are the point of medical training.
Other names rotate through the hype cycle—NAD boosters, senolytics, various peptides. A few have early data. Almost none have the long, clean outcomes data you’d want before calling them settled longevity medicine.
If you are a patient with a condition these drugs treat, you already have a lane: evidence-based care. If you are healthy and curious, read primary papers, talk to a clinician who will say no when needed, and do not source mystery vials from the internet.
The grown-up stance is interest without cosplay.
Research participation in proper trials is a legitimate way to engage the frontier. Buying research chemicals labelled “not for human use” is how people become cautionary tales rather than data points.
Interest without cosplay
Metformin, rapamycin analogues, GLP-1s, and other watched agents each have different risk profiles and evidence levels. Some are approved for other conditions; off-label longevity use is not a free upgrade.
Self-experimentation without medical oversight is how forums collect cautionary tales. If a drug interests you, bring it to a clinician who knows your history—not only a podcast transcript.
Keep your head while the field moves
Longevity science rewards patience. Prefer primary trials and careful explainers over certainty theatre. Use what changes your week—sleep, strength, screening conversations—while longer-horizon tools mature in public.
Independent News for Longevity will keep separating infrastructure from immortality marketing. That filter is how readers stay usefully informed without living in a permanent product launch.
Readers who want a single takeaway can use this: prefer actions you can repeat next month over stories that only raise your pulse for an afternoon. Independent News for Longevity is built for that slower kind of attention—science and habits that still matter when the feed has moved on.